STUB1 and myeloid neoplasm: Notably, the presence of pretransplant CHIP in autologous‐HSCT patients associates with increased risk for development of so called “therapy‐related” myeloid neoplasms (t‐MNs) and inferior overall survival, driven by t‐MNs and by non‐relapse‐associated adverse events [58].